11,832 Shares in ACADIA Pharmaceuticals Inc. $ACAD Bought by Cetera Investment Advisers

Cetera Investment Advisers purchased a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 11,832 shares of the biopharmaceutical company’s stock, valued at approximately $197,000.

A number of other institutional investors also recently bought and sold shares of the business. Burney Co. increased its stake in ACADIA Pharmaceuticals by 5.1% in the first quarter. Burney Co. now owns 398,092 shares of the biopharmaceutical company’s stock valued at $6,612,000 after purchasing an additional 19,189 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in ACADIA Pharmaceuticals in the first quarter valued at $1,776,000. Teachers Retirement System of The State of Kentucky acquired a new position in ACADIA Pharmaceuticals in the first quarter valued at $706,000. Hollencrest Capital Management increased its stake in ACADIA Pharmaceuticals by 333.3% in the first quarter. Hollencrest Capital Management now owns 6,500 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 5,000 shares during the period. Finally, CWM LLC increased its stake in ACADIA Pharmaceuticals by 50.1% in the first quarter. CWM LLC now owns 5,845 shares of the biopharmaceutical company’s stock valued at $97,000 after purchasing an additional 1,951 shares during the period. 96.71% of the stock is currently owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Price Performance

Shares of NASDAQ ACAD opened at $25.74 on Friday. ACADIA Pharmaceuticals Inc. has a 12-month low of $13.40 and a 12-month high of $25.88. The company has a market capitalization of $4.34 billion, a PE ratio of 19.35, a price-to-earnings-growth ratio of 6.31 and a beta of 0.70. The firm’s 50-day moving average is $23.02 and its two-hundred day moving average is $19.71.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.02. ACADIA Pharmaceuticals had a net margin of 21.80% and a return on equity of 14.69%. The company had revenue of $264.57 million for the quarter, compared to the consensus estimate of $263.07 million. During the same quarter in the prior year, the firm earned $0.20 earnings per share. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. On average, analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price target for the stock from $20.00 to $35.00 in a research note on Wednesday, May 21st. Bank of America boosted their price target on shares of ACADIA Pharmaceuticals from $18.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, June 5th. The Goldman Sachs Group boosted their price target on shares of ACADIA Pharmaceuticals from $15.00 to $17.00 and gave the stock a “sell” rating in a research note on Thursday, August 7th. UBS Group boosted their price target on shares of ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the stock a “buy” rating in a research note on Friday, August 8th. Finally, Mizuho boosted their price target on shares of ACADIA Pharmaceuticals from $23.00 to $24.00 and gave the stock a “neutral” rating in a research note on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, ACADIA Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $28.88.

Insider Buying and Selling

In other news, EVP Mark C. Schneyer sold 22,000 shares of the business’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $25.18, for a total value of $553,960.00. Following the completion of the transaction, the executive vice president owned 40,130 shares of the company’s stock, valued at $1,010,473.40. The trade was a 35.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Laura Brege sold 14,446 shares of the business’s stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $21.78, for a total transaction of $314,633.88. Following the completion of the transaction, the director directly owned 15,095 shares of the company’s stock, valued at approximately $328,769.10. This represents a 48.90% decrease in their position. The disclosure for this sale can be found here. Insiders own 26.50% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.